Abstract
COVID-19 cases have peaked and declined rapidly in many low- and middle-income countries in recent months, in some cases after control measures were relaxed. For 11 such countries, the hypothesis that COVID-19 cases have declined mainly through low susceptibility levels, stemming largely from high levels of infection leading to (at least temporary) immunity, warrants serious consideration. The Reed-Frost model, perhaps the simplest description for the evolution of cases in an epidemic, with only a few constant parameters, fits the observed case data remarkably well, and yields parameter values that are reasonable. The model results give infection levels of 45% and 79%, above the herd immunity threshold for each country under their current social distancing conditions. Reproduction numbers range between 1.4 and 2.0, indicating that epidemic curves were “flattened” but not “suppressed”. Between 0.05% and 2.86% of cases have been detected according to the estimates – values which are consistent with findings from serological studies. Overall infection fatality ratios for two of three countries studied are lower than expected from reported infection fatality ratios by age (which are based on studies of several high-income countries). COVID-19 may have lower age-specific fatality risks in some countries, due to differences in immune-response, prior exposure to coronaviruses, disease characteristics or other factors. We find that the hypothesis of control through low susceptibility would not have fit the evolution of reported cases in several European countries, even just after the initial peaks; instead, these countries reduced COVID-19 cases initially through disease control measures – and subsequent resurgences of cases obviously prove that those countries have infection levels well below those required for herd immunity. Our hypothesis that the 11 countries we studied have low susceptibility levels should now be tested further through immunity studies, and efforts should continue to determine the duration and extent of immunity to SARS-CoV-2 after infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received to support this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used only publicly available, anonymised data and applied only statistical analysis on this data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Please refer to the [updated] Supplementary materials (which is the appropriate version for this manuscript). Improved explanation of comparison to serology studies. Refined link to T-cell-mediated immunity. Adjusted language throughout to improve readability.
Data Availability
All data used is publicly available data (as published by WHO). Relevant sources are included in footnotes where applicable. All equations and methods used in this article are described in the supplementary material which we submit at the same time as a separate publication.
